Introduction
Central nervous system (CNS) disorders often accompany the acquired immunodeficiency syndrome (AIDS) and are typified by neuropsychiatric symptoms, such as cognitive and motor impairments (Lanska 1999; McArthur et al. 2004; Lipton and Gendelman 2005; Tattevin et al. 2006) , sometimes paralleled by neuropathological hallmarks. Collectively, these events are referred to as human immunodeficiency virus-1 (HIV-1)--associated dementia (HAD) . Before the advent of the highly active antiretroviral therapy (HAART), about 20% of adult patients but as many as 40% of children/adolescent infected subjects developed HAD. Nowadays, in the era of HAART, the prevalence of HAD has decreased, but a more subtle form of disorder, referred to as minor cognitive--motor disorder The mechanisms underlying the AIDS-related neuropsychiatric symptoms are poorly understood, but the possibility exists that, besides evident neurotoxic damages, subtle modulations of neurotransmission are caused by proteins shed by the virus or actively released by HIV-1--infected cells in the CNS (Ensoli et al. 1993; Kaul et al. 2005) , as well as by endogenous factors whose production is triggered by the viral infection Pocernich et al. 2005) . Among the many candidates, the viral protein transactivator of transcription (Tat) has attracted much interest. In the CNS, this protein is secreted by infected cells, including microglia, astrocytes, and macrophages (King et al. 2006) . Tat mRNA levels are elevated in the serum and in the brain of patients with HIV-1 dementia (Wessenligh et al. 1993; Westendorp et al. 1995) or HIV encephalitis (Wiley et al. 1996) . Furthermore, when introduced into the CNS, exogenous Tat was reported to produce pathological effects similar to those observed in HAD patients (Kim et al. 2003; Maragos et al. 2003) .
Tat can excite neurons (Sabatier et al. 1991; Nath and Geiger 1998) and mobilize Ca 2+ from intracellular stores (Haughey et al. 2001; Feligioni et al. 2003) , compatible with a potential role of neurotransmitter release modulator. Accordingly, the protein was shown to enhance the basal release of acetylcholine from human and rodent neocortical cholinergic terminals (Feligioni et al. 2003) . This Tat-mediated release appeared restricted to the cholinergic terminals because the basal release of other neurotransmitters, including glutamate and c-aminobutyric acid (GABA), was not modified by the protein (Feligioni et al. 2003) . We have now reconsidered this topic by investigating whether Tat could affect the exocytosis of glutamate and GABA evoked by depolarizing stimuli from human and mouse neocortical nerve endings. Tat facilitated glutamate exocytosis by acting as an extremely potent agonist at metabotropic glutamate (mGlu) 1 autoreceptors located on human and mouse neocortical glutamatergic nerve endings. Although mGlu5 autoreceptors seem not directly involved, their presence seems to be required for the expression of functional mGlu1 autoreceptors. Surprisingly, Tat potently inhibited GABA exocytosis by acting at hitherto unknown binding sites on GABAergic nerve endings. The unbalance between glutamate and GABA transmission may play a role in the neuropsychiatric disorders characteristic of HAD and MCMD.
Materials and Methods

Human Brain Tissue Samples
Samples of human cerebral cortex were obtained from informed and consenting HIV-1--negative patients undergoing neurosurgery to reach deeply seated tumors. The samples represented parts of frontal, parietal, and temporal lobes obtained from 10 women and 21 men (ages 24--70 years). Patients had been treated with levetiracetam (1 g every 12 h) starting from 24 h before neurosurgery. After a premedication with midazolam (2 mg/kg), anesthesia was induced with propofol (2 mg/kg), cisatracurium (10--14 mg), and fentanyl (0.1 mg) and maintained with propofol (5 lg/kg/h) and remifentanyl (0.005--0.008 lg/min) during neurosurgery. Immediately after removal, the tissue was placed in a physiological salt solution at 2--4°C, and purified synaptosomes were prepared within 30--40 min. The experimental procedure was approved by the Ethical Committee of the University of Genova.
Animals
Adult male mice (Swiss; 20--25 g) were used in all the experiments except those carried out with mGlu1 receptor lacking cervelet-4 (crv4) mice and mGlu5 -/-receptor knockout mice. The crv4 mutation is a spontaneous recessive mutation occurred in the BALB/c/Pas inbred strain. It consists in an LTR intronic insertion that disrupts splicing of mGlu1 receptor gene and causes absence of the protein (Conti et al. 2006) . Crv4 homozygous mice present mainly with an ataxic phenotype. Affected (crv4/crv4) and control (+/+) mice are maintained on the same genetic background by intercrossing +/crv4 mice at the animal facility of the National Institute of Cancer Research (Genova, Italy). DNA was extracted from wild-type and crv4 mice tails and was amplified via polymerase chain reaction (PCR) using primers (5#-GAGTGTTCACTAGTTCACCCAAGA-3# and 5#-TCAGGCAACAA-TAAGGCAAG-3#) that flank the insertion; the PCR products amplified with these primers were 688 bp for the crv4 mutant and 498 bp for the wild type (see also . Heterozygous mGlu5 receptor knockout mice (129-Gprc1e tmt1rod ) were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice heterozygous for the targeted mutation were intercrossed to homozygosity at the ''Istituto Neurologico Mediterraneo Neuromed'' (Pozzilli, IS, Italy). Homozygous females and males were fertile but poor breeders. Thus, all mice were generated by heterozygous breeding. Primers for the genotyping of knockout mice were designed at the Jackson Laboratory. Mice were identified by PCR analysis of tail samples after birth. Transgenic mice were then sent to the animal facility of our laboratory (Department of Experimental Medicine, Pharmacology and Toxicology Section, University of Genoa). Mice were kept under environmentally controlled conditions (ambient temperature = 22 ± 1°C, humidity = 50%) on a 12-h light/dark cycle with food and water ad libitum.
The animals were killed by decapitation, brain cortices were rapidly removed, and purified synaptosomes or slices were prepared within minutes. The experimental procedures were approved by the Department Ethical Committee, in accordance with the European legislation (European Communities Council directive of November 24, 1986, 86/609/EEC). Experiments were performed following the Guide for the Care and the Use of laboratory animals of the National Institutes of Health (NIH publication No. 86-23, revised 1987) . Adequate measure was taken to minimize pain or discomfort.
Preparation of Synaptosomes
Purified synaptosomes were prepared essentially according to Dunkley et al. (1986) , with minor modifications. The tissue was homogenized in 10 volumes of 0.32 M sucrose, buffered to pH 7.4 with Tris (final concentration 0.01 M) using a glass Teflon tissue grinder (clearance 0.25 mm). The homogenate was centrifuged at 1000 3 g for 5 min to remove nuclei and debris, and the supernatant was gently stratified on a discontinuous Percoll gradient (6%, 10%, and 20% v/v in Tris-buffered sucrose) and centrifuged at 33 500 3 g for 5 min. The layer between 10% and 20% Percoll (synaptosomal fraction) was collected and washed by centrifugation. The synaptosomal pellets were always resuspended in a physiological medium having the following composition (mM): NaCl, 125; KCl, 3; MgSO 4 , 1.2; CaCl 2 , 1.2; NaH 2 PO 4 , 1; NaHCO 3 , 22; glucose, 10 (aeration with 95% O 2 and 5% CO 2 ); pH 7.2--7.4. In GABA release experiments, the medium contained aminooxyacetic acid, 50 lM, to avoid GABA metabolism. Synaptosomal protein contents were determined according to Bradford (1976 When studying the effects of Tat-and of mGlu1/5-selective ligands on the basal release of neurotransmitters, synaptosomes were first equilibrated during 36 min of superfusion and then 4 consecutive 3-min fractions (termed b1--b4) were collected. Compounds were introduced at the end of the first fraction collected (b1; t = 39 min) and maintained until the end of the superfusion. When studying the effect of Tat and of (RS)-3,5-dihydroxyphenylglycine (3,5-DHPG) on neurotransmitter overflows evoked by high K + , synaptosomes were transiently (90 s) exposed at t = 39 min to a solution containing 12 mM KCl (NaCl substituting for an equimolar concentration of KCl). Tat or 3,5-DHPG was added concomitantly with the depolarizing stimulus. Antagonists were added 8 min before agonists. In these experiments, fractions were collected according to the following scheme: two 3-min fractions (basal release), one before (t = 36--39 min, b1) and one after (t = 45--48 min, b3), and a 6-min sample (t = 39--45 min; evoked release, b2) containing the transmitter released by the depolarizing stimulus. Superfusion was always performed with medium enriched with dialyzed 0.1% of Polypep to avoid protein sticking to glass walls and tubings. Collected fractions and superfused synaptosomes were counted for radioactivity or analyzed for the endogenous neurotransmitter content. Bradford (1976) .
Experiments of Release from Superfused Slices
Isolation of Detergent-Soluble Fractions from Synaptosomes
Purified synaptosomes were prepared as previously described (Musante, Longordo, et al. 2008 ) and collected by centrifugation at 14 000 3 g for 15 min at 4°C. The pellet was diluted and lysed in 1 ml of ice-cold 20 mM Tris/HCl (pH 7.4, containing 10 mM NaCl and protease inhibitor cocktail). In order to isolate the detergent-soluble membrane fraction (DS-Syn), after 15 min at 4°C, 450 lg of synaptosome lysate (Tot-Syn) were centrifuged at 200 000 3 g, 4°C for 15 min, and the pellet was solubilized in 800 ll of 20 mM Tris/HCl (pH 7.4, containing 140 mM NaCl, 0.2% Triton X-100, and protease inhibitor cocktail). After 15 min at 4°C, samples were centrifuged at 200 000 3 g, 4°C for 15 min, and the supernatant, the DS-Syn, was collected. Proteins were quantified using the Pierce BCA Protein Assay Kit (Pierce Biochemical, Rockford, IL).
Immunoprecipitation DS-Syn (100 lg of proteins) was diluted in 0.5 ml of Triton X buffer having the following composition: 20 mM Tris/HCl, 140 mM NaCl, protease inhibitors, 0.5% (v/v) Triton X-100, pH 7.4, and precleaned by incubating the suspension with 20 ll of protein A--agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 1 h. Bead suspension was centrifuged and the supernatant incubated with 6 lg of the specific antibody (anti-mGlu1 or mGlu5 receptor antibody) at 4°C overnight. The supernatant was added with 30 ll of protein A--agarose beads, incubated for 1 h at 4°C, and the bead suspension was centrifuged. The pellet was subjected to 5 3 0.2 ml washes with the Triton X buffer, followed by 5 3 0.2 ml washes with the same buffer from where Triton X-100 was removed. The adsorbed proteins were resuspended in sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS-PAGE) loading sample buffer and eluted by heating the suspension for 5 min at 95°C.
Immunoblotting
Proteins (25 lg/lane) were separated by SDS-PAGE 7.5% polyacrylamide and then transferred onto polyvinylidene difluoride membranes. Membranes were blocked in 20 mM sodium phosphate buffer (PBS, pH 7.4, containing 140 mM NaCl, 5% nonfat dry milk, 0.1% Tween-20) and probed with one of the following primary antibodies (60 min at 20°C): rabbit anti-mGlu1 receptor (1:500), rabbit anti-mGlu5 receptor (1:1000), mouse anti-syntaxin-1A (anti Stx-1A, 1:5000), and mouse anti-glial fibrillary acidic protein (anti-GFAP, 1:1000) as appropriate. After extensive washes, membranes were incubated for 1 h at 20°C with the appropriate horseradish peroxidase--linked secondary antibody (1:4000), and immunoblots were visualized with an enhanced chemiluminescence western blotting detection system.
Calculations
The amount of endogenous amino acid from neocortical synaptosomes in each superfusate fractions was expressed as picomoles per milligram per protein (pmol/mg/protein). The effects of Tat on the basal release of endogenous transmitters were evaluated by calculating the ratio between the amino acid content in the fraction where the maximal effect was reached (the third fraction collected) and the amount in the first fraction and comparing this ratio with the corresponding ratio obtained under control conditions (no drug added). The amount of radioactivity released into each superfusate fraction was expressed as % of the total synaptosomal tritium content at the start of the fraction collected (fractional efflux). Drug-induced changes to the spontaneous release of tritiated neurotransmitters from neocortical synaptosomes were expressed as % increase over basal release and were evaluated as the ratio between the percentage of tritium released into the third fraction and that in the first fraction collected. This ratio was compared with the corresponding ratio obtained under control conditions (no drug added). The K + -induced overflow of endogenous neurotransmitters from neocortical synaptosomes was expressed as pmol/mg protein, whereas the induced tritium overflow was expressed as % of total radioactivity. In both cases, the induced overflow was estimated by subtracting the neurotransmitter content into the first and the third fractions collected (basal release, b1 and b3) from that in the 6-min fraction collected during and after the depolarization pulse (evoked release, b2). When the time course of drug-induced modification to K + -evoked endogenous neurotransmitter release is described, endogenous neurotransmitter released in each superfusate fractions was expressed as pmol/mg protein. When the time course of drug-induced modification to K + -evoked tritiated neurotransmitter release is described, the amount of radioactivity in each superfusate fraction collected is expressed as % of the total synaptosomal tritium content at the start of the fraction collected (fractional efflux).
The tritium overflow evoked by the depolarizing stimuli from slices was expressed as induced overflow and was calculated by subtracting the neurotransmitter content into the second and the fifth fractions collected (basal release) from that in the third and fourth fractions collected (evoked release). Endogenous IP 3 content in synaptosomal supernatant was expressed as pmol/mg protein. Analysis of variance was performed followed by Newman Keuls or Dunnett's multiple comparison test, as appropriate; direct comparisons were performed by applying Student's t-test. Data were considered significant for P < 0.05. Appropriate controls with antagonists were always run in parallel. . Anti-mGlu5 receptor polyclonal rabbit immunoaffinity-purified IgG and anti-mGlu1 receptor polyclonal rabbit immunoaffinity IgG were purchased from Upstate Biotechnology (Lake Placid, NY). Anti-syntaxin-1A monoclonal mouse IgG was obtained from Synaptic System (Germany). Horseradish peroxidase--conjugated anti-mouse and anti-rabbit secondary antibodies and the ECL Plus western blotting detection system were purchased from GE Healthcare. Recombinant Tat corresponded to the full-length sequence of the protein (aa1-86); Tat was kindly gifted by Centre for AIDS Reagents (supported by EU Programme EVA/MRC, contract QLK2- CT-1999-00609) (Fig. 1B) . Tat failed to affect the poststimulation neurotransmitter baseline (Fig. 1C,D) (Feligioni et al. 2003) . The neurotoxic fragment Tat 37--72 (1 nM) mimicked the entire protein in facilitating glutamate exocytosis and in inhibiting K + -evoked GABA release; on the contrary, Tat 48--85 (1 nM), a fragment peptide devoid of neurotoxicity (Sabatier et al. 1991; Nath et al. 1996) , failed to affect glutamate and GABA exocytosis ( Table 1) .
The Tat-induced effects can be attributed to direct action of the protein on glutamatergic and GABAergic nerve terminals because the characteristics of the technique used to monitor release (up--down superfusion of monolayers of purified synaptosomes) prevent or minimize indirect effects (see Raiteri and Raiteri 2000) .
The Tat Facilitation of [ 3 H]D-ASP Release from Human Neocortex Nerve Endings Is Sensitive to an mGlu1 Receptor Antagonist
Previous results had shown that group I mGlu receptors mediated the effects of Tat on the basal release of acetylcholine and noradrenaline in human brain (Feligioni et al. 2003; Longordo et al. 2006) . We therefore investigated whether group I mGlu receptors could also mediate the Tat effects here observed. CPCCOEt, a selective mGlu1 receptor antagonist, and MPEP, a selective mGlu5 receptor antagonist, were tested against the effects of Tat on the release of glutamate and GABA evoked by 12 mM K + from human neocortical synaptosomes.
CPCCOEt and MPEP were added at concentrations (5 and 1 lM, respectively) previously shown to prevent Tat effects under our experimental conditions (Feligioni et al. 2003; Longordo et al. 2006 ( Fig. 3B,D) . The mGlu1/5 receptor agonist left unmodified the poststimulation neurotransmitter baseline (Fig. 3C) . The pharmacological characterization of the mGlu receptors involved was then carried out using CPCCOEt and MPEP. The effect of 3,5-DHPG was halved by 1 lM MPEP but totally prevented by CPCCOEt (Fig. 3A) . The antagonists failed to affect on their own the spontaneous ( (Fig. 3B,D) . In order to ascertain the existence of mGlu1 and/or mGlu5 receptor proteins in human neocortical terminals, DS-Syn isolated from purified synaptosomes were probed with antimGlu1 and anti-mGlu5 receptor antibodies. To validate the purity of the synaptosomal membrane preparations, we also investigated the presence of the selective neuronal marker Stx-1A. The presence of the GFAP, a specific astrocyte marker, was also evaluated: GFAP immunoreactivity was barely detectable, suggesting that, in our synaptosomal preparations, contamination by gliosomes is very low (not shown, but see Musante, Longordo, et al. 2008 ). Selective antibodies recognized immunoreactive protein components with an apparent mass corresponding to those of mGlu1 and 5 receptors, respectively (Fig. 3C) , suggesting the existence of both receptors in human neocortex. By combining the results from release experiments with those from western blot and considering that glutamatergic nerve terminals are extremely abundant in the neocortex (~80% according to Milla´n et al. 2003) , it seems reasonable to assume that presynaptic mGlu1 and mGlu5 autoreceptors exist on human glutamatergic nerve endings. Coexistence on the same terminal remains to be established.
Effects of Tat on Glutamate and GABA Release Evoked by KCl from Mouse Neocortical Synaptosomes
It was important to verify if the effects of Tat observed in human brain could be reproduced in a laboratory animal that could become an appropriate model to further study the effects of Tat in the CNS. In mouse neocortical synaptosomes, as in human neocortical nerve endings (Feligioni et al. 2003) , Tat failed to affect significantly the spontaneous release of tritium content, nonsignificant [NS] ), but the protein facilitated the release induced by 12 mM K + (Fig. 4A) . Similarly, the basal release of endogenous glutamate from mouse neocortical synaptosomes was not modified by Tat (control = 85.3 ± 9.6; 1 nM Tat = 97.5 ± 10.2, n = 3, results expressed as pmol/mg protein, NS), whereas the 12 mM K + -evoked glutamate exocytosis was increased (Fig. 4B) . Analysis of the time course relationship of Tat-induced facilitation of glutamate and [ 3 H]D-ASP exocytosis showed that the viral protein did not cause modifications to poststimulation neurotransmitter baseline (Fig. 4C,D) .
Tat also failed to affect the spontaneous release of [ 3 H]GABA (control = 2.76 ± 0.25%; 1 nM Tat = 3.01 ± 0.32%, n = 4, results expressed as % of total synaptosomal content, NS), but it inhibited the 12 mM K + -evoked exocytosis of the tritiated neurotransmitter from mouse neocortical synaptosomes (Fig. 5A ). The basal release of endogenous GABA was insensitive to the viral protein (control = 55 ± 5.7; 1 nM Tat = 43.5 ± 8.2 pmol/mg protein (n = 3), but the 12 mM K + -evoked exocytosis of GABA was significantly reduced by Tat (Fig. 5B) . Again, the analysis of the time course relationship of Tat-induced facilitation of GABA and [
3 H]GABA exocytosis demonstrated that changes did not occur to poststimulation neurotransmitter baseline (Fig. 5C,D) . Also in this case, the neurotoxic fragment Tat 37--72 (1 nM) mimicked the entire protein in facilitating glutamate exocytosis and in inhibiting K + -evoked GABA release from mouse neocortical synaptosomes, whereas Tat 48--85 (1 nM) was inactive (Table 1) . (Fig. 6A) . CPCCOEt did not affect the K + -evoked release of endogenous glutamate but blocked the release-enhancing effect of 1 nM Tat (Fig. 6B) . On the contrary, the effect of Tat was not prevented by 1 lM MPEP (Fig. 6B) (Table 2) .
CPCCOEt and MPEP had no effect, on their own, on the spontaneous ( (Table 2 and Fig. 6C and D) . Neither of the 2 antagonists was able to prevent the inhibitory effect of 1 nM Tat on the K + -evoked release of [ 3 H]GABA (Fig. 6C ) or of endogenous GABA (Fig. 6D) . Furthermore, 3,5-DHPG failed to modify the 12 mM K + -evoked release of GABA from mouse neocortical 
Deletion of mGlu1 or mGlu5 Receptors Prevents the Facilitation of Glutamate Exocytosis but not the Inhibition of GABA Exocytosis Caused by Tat in Mouse Cortical Synaptosomes
To better understand the role of mGlu1 and mGlu5 autoreceptors in the Tat-induced facilitation of glutamate release, the effects of Tat were investigated in synaptosomes isolated from the cerebrocortex of mouse lacking mGlu1 (crv4/crv4 mice, see Fig. 7C ) or mGlu5 (mGlu5 -/-mice) receptors. As already reported , the 12 mM
synaptosomes was significantly greater (+50, 76 ± 7.3%, P < 0.05) than that released from control synaptosomes. In contrast, deletion of the mGlu5 receptor subtype did not affect the tritium released by the depolarizing stimulus (Fig. 6A , . Lack of either mGlu1 or mGlu5 receptors prevented the enhancing effects of Tat on glutamate exocytosis (Fig. 6A) . Indeed, the viral protein, added at 1 nM, failed to facilitate the 12 mM K + -evoked release of [ 3 H]D-ASP not only from crv4/crv4 but also from mGlu5 -/-neocortical synaptosomes (Fig. 6A) . These results are compatible with the idea that mGlu1 and mGlu5 receptor interact with each other, perhaps, because they are coexpressed on the same glutamatergic nerve endings as previously hypothesized . To further test this hypothesis (or further support these findings), we immunoprecipitated mGlu1 and mGlu5 receptor proteins and, subsequently, analyzed the immunoprecipitates with mGlu5 and mGlu1 receptor antibodies. Immunoprecipitation of neocortical synaptosomes with the anti-mGlu1 receptor antibody produced a marked signal for the mGlu5 receptor protein and vice versa (Fig. 7D) .
Considering that glutamatergic terminals represent by far the most abundant of the cortical synaptosomal populations (Milla´n et al. 2003) , it seems reasonable to assume that mGlu1 and mGlu5 autoreceptors coexist on glutamatergic nerve endings. Deletion of mGlu1 or mGlu5 receptors failed to affect the amount of [ 3 H]GABA released by 12 mM KCl. Furthermore, the inhibition of the evoked [ 3 H]GABA exocytosis by 1 nM Tat was not modified in synaptosomes prepared from crv4/crv4 or mGlu5 -/-mice (Fig. 7B ).
Tat Stimulates IP 3 Production in Human and Mouse Neocortical Synaptosomes
Human and mouse neocortical synaptosomes were analyzed for their endogenous IP 3 content. Synaptosomes were first analyzed for their IP 3 content in control (in the absence of depolarizing stimulus) and in depolarizing (i.e., exposure to 12 mM K + ) conditions; the results indicate that depolarization increases, although not significantly, the endogenous synaptosomal amount of the second messenger. We then investigated the impact of Tat on the 12 mM K + -evoked IP 3 production. Table 3 shows that the addition of 1 nM Tat almost doubled the endogenous IP 3 content in human neocortical synaptosomes exposed to 12 mM KCl. Concomitant addition of 5 lM CPCCOEt significantly reduced the endogenous content of the second messenger in human neocortical synaptosomes exposed to 12 mM KCl/1 nM Tat. Similarly, Tat significantly increased the endogenous IP 3 content in mouse neocortical synaptosomes depolarized with 12 mM K + . Again, the 12 mM KCl/1 nM Tat-induced IP 3 production was abolished by 5 lM CPCCOEt (Table 3) . Similar results were obtained when analyzing the effect of 3,5-DHPG on the 12 mM K + -evoked production of IP 3 . Table 3 shows that 50 lM 3,5DHPG significantly increased the endogenous IP 3 content in both human and mouse neocortical synaptosomes. In both cases, the 3,5DHPG-induced IP 3 production was largely prevented by 5 lM CPCCOEt. CPCCOEt did not modify, on its own, the IP 3 content in human and mouse neocortex synaptosomes exposed to 12 mM K + (data not shown). 3 H]GABA were first exposed in superfusion to 1 nM Tat. Under these conditions, the protein was unable to modify the basal release of radioactivity (data not shown).
We then studied the effects of Tat on the release of To further support the involvement of mGlu1 receptors in the Tat-induced glutamate release, neocortical slices were prepared from crv4/crv4 mice and exposed to 10 lM veratridine alone or in the presence of 1 nM Tat. The veratridine-induced [
3 H]D-ASP release in crv4/crv4 neocortical slices did not differ significantly from that in control slices. The lack of mGlu1 receptors totally impeded the effect of Tat on the veratridine-induced overflow (Fig. 8B) .
Discussion
The principal finding of the present investigation is that low nanomolar concentrations of the HIV-1 viral protein Tat can exert opposite effects on the depolarization-evoked release of the two major neurotransmitters of the mammalian CNS. Tat facilitated the exocytosis of the excitatory neurotransmitter glutamate but decreased that of the inhibitory neurotransmitter GABA from human neocortical nerve endings. The effects of Tat may therefore cause unbalances between excitation and inhibition in neuronal circuitries involved in HAD and MCMD. Tat appears to activate directly release-enhancing glutamate autoreceptors belonging to the mGlu1 subtype. The targets that mediate the inhibition of GABA release remain to be identified. The data obtained with mouse synaptosomes The possibility that Tat modulates glutamatergic neurotransmission in the CNS had been already considered on the basis of its excitotoxic effects (Nath et al. 1996; Cheng et al 1998) . Tat was found to regulate extracellular glutamate levels in human cortical cultured cells (Eugenin et al. 2003) , to enhance glutamate transmission in the mouse suprachiasmatic nucleus (Clark et al. 2005) and to increase the frequency of miniature excitatory postsynaptic currents in rat cortical neurons (Brailoiu et al. 2008 ). This latter observation was considered predictive of a presynaptic effect, which is confirmed by the present results showing that Tat could facilitate glutamate exocytosis from adult human and mouse neocortical nerve terminals.
The facilitation of glutamate release is due to activation by Tat of group I mGlu presynaptic autoreceptors. In particular, based on the results with selective group I mGlu receptor antagonists, mGlu1 receptors seem to play the major role because Tat facilitation of glutamate exocytosis from human and mouse neocortical nerve endings was antagonized by CPCCOEt but scarcely inhibited by MPEP. Group I mGlu receptors are known to trigger phospholipase C--dependent IP 3 production and consequent Ca 2+ mobilization from the endoplasmic reticulum (Ferraguti et al. 2008) . In line with the proposed involvement of IP 3 -linked group I mGlu receptors, a significant production of IP 3 was induced by Tat both in human and mouse neocortical synaptosomes.
The existence of release-enhancing mGlu autoreceptors of group I on glutamate nerve endings of rodent cerebrocortex, first described by Herrero et al. (1992) , has been the object of several studies (see, for a recent review, Raiteri 2008) . Most authors classified these autoreceptors as mGlu5 subtype (Rodriguez-Moreno et al. 1998; Sistiaga et al. 1998; Fazal et al. 2003; Rodrigues et al. 2005) , although evidence has been provided that mGlu1 receptors may also be present on glutamatergic terminals of rodent brain (Reid et al. 1999 . The apparent discrepancies seem to have been clarified by who found that, in mouse nerve endings, the group I mGlu receptor agonist 3,5-DHPG enhanced the evoked release of [ 3 H]D-ASP through mGlu5 autoreceptors when added at low micromolar concentrations ( <1 lM) but also through mGlu1 autoreceptors when added at concentrations >30 lM. Here we show that group I mGlu autoreceptors of the mGlu1 subtype also exist on human neocortical glutamatergic terminals, based on the findings that 1) 3,5-DHPG, added at 50 lM, potentiated the K + -evoked release of glutamate; 2) this potentiation was totally antagonized by CPCCOEt but only in part by MPEP, as expected if 3,5-DHPG preferentially activated mGlu1 autoreceptors; and 3) based on western blot data, both mGlu1 and mGlu5 receptor exist on human synaptosomal membranes. Consistent with a prevalent role of mGlu1 receptors in the releasing effect of Tat, synaptosomes from animals lacking mGlu1 (crv4/crv4 mice) exhibited no functional responses to Tat. Curiously, however, Tat was also devoid of efficacy in synaptosomes prepared from the cortex of mGlu5 -/-mice, a finding in apparent contrast with the poor ability of MPEP in antagonizing the Tat-induced facilitation of glutamate release in wild-type mice. Previous results, however, had shown that mGlu1 receptor-mediated functions, including the presynaptic control of glutamate release, were altered in mGlu5 -/-mice (Volk et al. 2006; ). These observations could be predictive of a physical connection between mGlu1 and mGlu5 receptor proteins; on the other hand, they also suggest that there may be alterations in mGlu1 receptor localization and function consequent to mGlu5 deletion. The functional observations in knockout mice, together with the results from western blot analysis showing coimmunoprecipitation of mGlu1 and mGlu5 receptor proteins, support the idea that mGlu5 autoreceptors exert a permissive role on the function of co-existing mGlu1 autoreceptors. If this were the case, the lack of efficacy of Tat in mGlu5 -/-synaptosomes would represent the consequence of the altered function of mGlu1 autoreceptors due to mGlu5 deletion, instead of suggesting a direct binding of Tat at mGlu5 autoreceptors.
It was proposed that Tat can act directly on G protein (Haughey et al. 2001) . In fact, the protein was found able to enter cells by process of internalization (Frankel and Pabo 1988; Ferrari et al. 2003) . This probably does not occur under our conditions because the lack of effect of Tat in neocortical synaptosomes from crv4/crv4 or mGlu5 -/-mice indicates that Tat directly binds at the mGlu receptor proteins (Longordo et al. 2006) .
The Tat-induced facilitation of glutamate exocytosis observed in isolated nerve endings could also be seen using much more intact preparations, that is, the mouse neocortical slices. Receptors of the mGlu1 subtype appear to play a major role also in neocortical slices because 1) CPCCOEt prevented the effect of the viral protein and 2) the facilitation by Tat of glutamate exocytosis could not be observed in slices from crv4/crv4 mice.
The low nanomolar concentrations of Tat (1--3 nM) that facilitated glutamate exocytosis inhibited the exocytosis of GABA from human and mouse neocortical nerve terminals. The characteristics of the superfusion technique used allow us to say that Tat acts directly on GABAergic nerve endings; however, the nature of the binding sites is at present unknown. Receptors of the mGlu1 or mGlu5 subtype appear not to be involved because selective antagonists could not prevent the inhibitory effect of Tat and 3,5-DHPG did not mimic Tat in inhibiting GABA exocytosis. Moreover, the Tat inhibition persisted in mice lacking mGlu1 or mGlu5 receptors.
The present results may have pathological implications. Considering that the concentrations of Tat here used are lower than those causing overt neurotoxicity (Magnuson et al. 1995; New et al. 1997; Cheng et al. 1998; Haughey et al. 2001) , the Tat-induced effects here observed may not necessarily represent steps on the path toward neurotoxicity. Importantly, the concentrations of Tat found to be active on the release are those measured in the CNS of AIDS patients (~2.5 nM, Westendorp et al. 1995) ; therefore, the impairments of neurotransmission consequent to enhancement of glutamate exocytosis and inhibition of GABA exocytosis may reasonably occur in the brain of HIV-1--infected patients. Glutamate receptors of the mGlu1 subtype may represent targets through which Tat can act as an extremely potent ''pathological agonist'' to produce impairments in glutamatergic (present results), cholinergic (Feligioni et al. 2003) , and noradrenergic (Longordo et al. 2006) neurotransmissions. It is surprising that mGlu1 autoreceptors require high micromolar concentrations of classic agonist to be activated but fully respond to 1--3 nM Tat. Because Tat may not be easily removed from the CNS of HIV-1--infected patients, mGlu1 receptors could be activated by Tat even in the presence of physiological levels of glutamate.
On the other hand, the Tat-induced reduction of GABA release should weaken the inhibition of glutamate exocytosis exerted by GABA spilling over onto presynaptic GABA B heteroreceptors presynaptically located on glutamatergic terminals (Raiteri 2006) , thus worsening the Tat-mediated exacerbation of glutamate transmission. These neurotransmitter unbalances may play roles in the neuropsychiatric manifestations, including loss of memory and seizures, often observed in HIV-1--infected patients (Bartolomei et al. 1999; Lawrence and Major 2002; Modi et al. 2002) and in part exhibited by animals administered Tat (Sabatier et al. 1991; Zink et al. 2002; Fitting et al. 2006) or expressing Tat in their CNS (Kim et al. 2003) .
To conclude, the available information (Feligioni et al. 2003; Longordo et al. 2006) together with the present results suggest that mGlu1/5 receptor negative modulators/antagonists, in association with HAART, could represent novel therapeutic agents able to relieve the neuropsychiatric symptoms characteristic of HAD and MCMD.
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